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Introduction
Conclusions
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Method
 Teriparatide [recombinant human PTH (1-34)] is an osteoanabolic agent 
for treatment of osteoporosis.
 Intermittent injection of low doses (20 µg) Teriparatide increases bone 
mineral density (BMD) and decreases the risk of vertebral and non-
vertebral fractures in post-menopausal women with osteoporosis. 
 Measurement of PTH (1-34) is valuable in assessing treatment response 
and concordance with therapy.
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HPLC Column
 Waters (UK) 
AQUITY UPLC®
Peptide CSH™ C18 
column 130 Å (1.7 
µm, 2.1 x 50 mm).
 Flow rate: 0.4 
mL/min
Sample preparation
Assay Validation
Aims and Objectives
 To develop and validate a method for quantification of PTH (1-34) using 
liquid-chromatography tandem mass spectrometry (LC-MS/MS).
 To perform method comparison with IDS-iSYS PTH (1-34) immunoassay kit 
(IDS, Boldon Tyne and Wear, UK).
 To highlight factors/interferences that may contribute to the difference in 
PTH (1-34) results on both LC-MS/MS and immunoassay methods.
LC-MS/MS system
Micromass Quattro 
Ultima triple 
quadrupole tandem 
mass spectrometer.
Figure (1). Typical calibration curve for hPTH (1-34) 
spiked into charcoal-stripped human EDTA plasma. 
R2 value is 0.999.
 Linear calibration curve from 
10 to 2000 pg/mL
 Typical linear regression 
analysis (r2 = 0.999)
 Lower limit of Quantification 
(LLoQ): 10 pg/mL
 Lower limit of detection 
(LLoD): 2.1 pg/mL
Imprecision :
Stock of hPTH (1-34) calibrators and controls were prepared in our laboratory by spiking high purity
(>98.0%) recombinant hPTH (1-34) (PROSPEC, NJ, USA) in charcoal-stripped human EDTA plasma. Intra-
imprecision profile was generated by running all QC samples 10 times within a single run, while inter-
imprecision profile was generated by repeated measurements (n=10) of all QCs over a period of a
month.
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QC Level 
(pg/mL)
Inter-assay imprecision Intra-assay imprecision
Mean SD SE %CV %Accuracy Mean SD SE %CV %Accuracy
QC1 (20) 24.4 2.4 0.8 9.8 102.0 20.8 1.6 0.5 7.8 99.6
QC2 (100) 108.5 8.9 2.8 8.2 100.9 102.1 7.1 2.2 6.9 99.8
QC3 (200) 212.8 13.8 4.4 6.5 100.6 201.9 14.7 4.7 7.3 99.9
QC4 (800) 828.0 42.4 13.4 5.1 100.4 816.2 19.0 6.0 2.3 99.8
Recovery efficiency:
Endogenous PTH(1-
34) (pg/mL)
Spiked (pg/mL)
Expected 
concentration 
(endogenous + 
spiked), pg/mL
Mean (±SD) 
measured hPTH (1-
34) (pg/mL)
%Recovery 
mean (%CV)
8.4 20 28.4 28.0 (±1.0) 98.6 (3.6)
8.4 800 808.4 883.4 (±31.4) 109.3 (3.6)
77.5 20 97.5 101.9 (±2.0) 104.5 (1.9)
77.5 800 877.5 990.3 (±11.8) 112.9 (1.2)
602.7 20 622.7 665.0 (±14.8) 106.8 (2.2)
602.7 800 1402.7 1560.8 (±111.3) 111.3 (7.1)
Ion Suppression
Method comparison
Interference/Cross-reactivity study
 Cross-reactivity of LC-MS/MS and IDS immunoassay to human PTH (1-84), rat PTH (1-
34), human PTH (13-34), human PTHrP (1-86), and PTHrP (1-36) was studied.
 The immunoassay showed a 7% cross-reactivity to human PTH (1-86) and 44% to rat
PTH (1-34), whilst no interference was observed in the LC-MS/MS method.
Oxidised PTH (1-34)
Figure (5). LC-MS/MS spectrum of plasma collected from a 
rat that has been given oral PTH (1-34). Sample was not 
treated with H2O2. Note the presence of oxidised PTH (1-34) 
peaks.
Figure (6). LC-MS/MS spectrum of plasma collected from a 
rat that has been given oral PTH (1-34). Sample was 
incubated with 0.1 M H2O2 for 60 min. Note the change in 
peak intensity of oxidised/non oxidised PTH (1-34) forms.
Cross-reactivity of IDS immunoassay to oxidised PTH (1-34) forms
Figure (7). Time-point profile of change in hPTH (1-34) (non-oxidised
form) concentration after treatment of human plasma spiked with
500 pg/mL hPTH (1-34) with 1 mM H2O2. A decline in non-oxidised
PTH (1-34) by time was observed with LC-MS/MS, whereas no
change was observe with IDS immunoassay. This indicates that
immunoassay detects both oxidised and non-oxidised forms of PTH
(1-34).
Figure (8). Illustration of time-point change in LC-MS/MS response
of single oxidised and non-oxidised forms of hPTH (1-34) when
human plasma spiked with 500 pg/mL hPTH (1-34) treated with 1
mM H2O2. The decline in non-oxidised PTH (1-34) level associated
with a concurrent increase in oxidised PTH (1-34) forms level.
 Our LC-MS/MS method showed good reproducibility, selectivity, sensitivity and recovery.
 LC-MS/MS method showed high correlation with commercial immunoassay with concentration-dependent,
negative bias of 35.5% across the range of (0-800 pg/mL).
Matrix effect, cross-reactivity of immunoassay kit to other PTH fragments, and interference from oxidised
forms of PTH (1-34) are likely to be the major contributors to the difference in results between the two
methods.
 LC-MS/MS result reflects the true status of biologically active form of PTH therapy and will help in better
patient management.
 Capability of being able to measure oxidised forms can help with drug development and increase the potency
of the drug.
 Due to the lack of reference standard materials and external proficiency scheme available for PTH (1-34), the
true accuracy to the actual endogenous PTH (1-34) concentration in human plasma can not be assessed at
present.
Comparison of the LC-MS/MS method with IDS-iSYS immunoassay for PTH (1-34) (n=390). 
 Suppression in baseline signals was observed  
during co-injection of extracted human plasma 
sample and post column infusion of PTH (1-34).
 hPTH (1-34) and the IS eluted away from 
suppression and enhancement areas.
 The two methods showed high correlation (R2 =0.95).
 LC-MS/MS assay showed an average negative bias of -35.5 pg/mL (p<0.0001).
 The negative bias is proportional/concentration-dependent across the concentration range (0-800 pg/mL).
 Violated dots (in green) more likely indicates hook-effect on immunoassay. 
Chromatograms showing elution time of non- /oxidised-
hPTH (1-34) forms and rat PTH (1-34) (IS)
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